Limits...
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.

Collette J, Bruyère O, Kaufman JM, Lorenc R, Felsenberg D, Spector TD, Diaz-Curiel M, Boonen S, Reginster JY - Osteoporos Int (2009)

Bottom Line: In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles.Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290).Strontium ranelate offers clinical benefits to women across a wide range of metabolic states.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biology, Bone and Cartilage Markers Laboratory, University of Liège, Liège, Belgium. J.Collette@chu.ulg.ac.be

ABSTRACT

Unlabelled: Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels of biochemical markers of bone formation and resorption. The vertebral anti-fracture efficacy of strontium ranelate was shown to be independent of baseline bone turnover levels.

Introduction: Bone turnover (BTO) levels vary among women at risk of osteoporotic fracture. Strontium ranelate is an anti-osteoporotic treatment increasing bone formation and reducing bone resorption. It was hypothesised that its anti-fracture efficacy would be independent of baseline BTO levels.

Methods: Post-menopausal women with osteoporosis from two pooled studies were stratified in tertiles according to baseline levels of two BTO markers: bone-specific alkaline phosphatase (b-ALP, n = 4995) and serum C-telopeptide cross-links (sCTX, n = 4891). Vertebral fracture risk was assessed over 3 years with strontium ranelate 2 g/day or placebo.

Results: In the placebo group, relative risk of vertebral fractures increased with BTO tertiles by 32% and 24% for patients in the highest tertile for b-ALP and CTX, respectively, compared to those in the lowest tertile. In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles. Significant reductions in vertebral fractures with strontium ranelate were seen in all tertiles of both markers, with relative risk reductions of 31% to 47% relative to placebo. Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290).

Conclusion: The vertebral anti-fracture efficacy of strontium ranelate was independent of baseline BTO levels. Strontium ranelate offers clinical benefits to women across a wide range of metabolic states.

Show MeSH

Related in: MedlinePlus

Incidence of vertebral fractures over 3 years in patients in the lowest (n = 881) and highest (n = 867) tertiles for both b-ALP and sCTX. SR strontium ranelate, PL placebo
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2801841&req=5

Fig2: Incidence of vertebral fractures over 3 years in patients in the lowest (n = 881) and highest (n = 867) tertiles for both b-ALP and sCTX. SR strontium ranelate, PL placebo

Mentions: Among patients who were in the lowest tertile for both b-ALP and sCTX (n = 881), strontium ranelate treatment produced a RR reduction of 33% compared to placebo (RR = 0.67, 95% CI [0.47; 0.95], p = 0.023; Fig. 2). Among patients in the highest tertile for both b-ALP and sCTX (n = 867), the relative risk reduction with strontium ranelate was 49% (RR = 0.51, 95% CI [0.37; 0.70], p <0.001). The fracture incidences in the strontium ranelate group were comparable, and the magnitude of the treatment effect was not significantly different between patients in the lowest and highest tertiles for both markers (interaction test p = 0.254).Fig. 2


Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.

Collette J, Bruyère O, Kaufman JM, Lorenc R, Felsenberg D, Spector TD, Diaz-Curiel M, Boonen S, Reginster JY - Osteoporos Int (2009)

Incidence of vertebral fractures over 3 years in patients in the lowest (n = 881) and highest (n = 867) tertiles for both b-ALP and sCTX. SR strontium ranelate, PL placebo
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2801841&req=5

Fig2: Incidence of vertebral fractures over 3 years in patients in the lowest (n = 881) and highest (n = 867) tertiles for both b-ALP and sCTX. SR strontium ranelate, PL placebo
Mentions: Among patients who were in the lowest tertile for both b-ALP and sCTX (n = 881), strontium ranelate treatment produced a RR reduction of 33% compared to placebo (RR = 0.67, 95% CI [0.47; 0.95], p = 0.023; Fig. 2). Among patients in the highest tertile for both b-ALP and sCTX (n = 867), the relative risk reduction with strontium ranelate was 49% (RR = 0.51, 95% CI [0.37; 0.70], p <0.001). The fracture incidences in the strontium ranelate group were comparable, and the magnitude of the treatment effect was not significantly different between patients in the lowest and highest tertiles for both markers (interaction test p = 0.254).Fig. 2

Bottom Line: In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles.Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290).Strontium ranelate offers clinical benefits to women across a wide range of metabolic states.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biology, Bone and Cartilage Markers Laboratory, University of Liège, Liège, Belgium. J.Collette@chu.ulg.ac.be

ABSTRACT

Unlabelled: Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels of biochemical markers of bone formation and resorption. The vertebral anti-fracture efficacy of strontium ranelate was shown to be independent of baseline bone turnover levels.

Introduction: Bone turnover (BTO) levels vary among women at risk of osteoporotic fracture. Strontium ranelate is an anti-osteoporotic treatment increasing bone formation and reducing bone resorption. It was hypothesised that its anti-fracture efficacy would be independent of baseline BTO levels.

Methods: Post-menopausal women with osteoporosis from two pooled studies were stratified in tertiles according to baseline levels of two BTO markers: bone-specific alkaline phosphatase (b-ALP, n = 4995) and serum C-telopeptide cross-links (sCTX, n = 4891). Vertebral fracture risk was assessed over 3 years with strontium ranelate 2 g/day or placebo.

Results: In the placebo group, relative risk of vertebral fractures increased with BTO tertiles by 32% and 24% for patients in the highest tertile for b-ALP and CTX, respectively, compared to those in the lowest tertile. In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles. Significant reductions in vertebral fractures with strontium ranelate were seen in all tertiles of both markers, with relative risk reductions of 31% to 47% relative to placebo. Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290).

Conclusion: The vertebral anti-fracture efficacy of strontium ranelate was independent of baseline BTO levels. Strontium ranelate offers clinical benefits to women across a wide range of metabolic states.

Show MeSH
Related in: MedlinePlus